b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling
Fin T A Brown, Lucy Quesne, Louisa M Wootton, Holly Foxell, Ipek Erseven, Emilia Ewen Benns, Molly Tate, Ethan L Morgan · 2026
Read b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling by Fin T A Brown, Lucy Quesne, Louisa M Wootton, Holly Foxell, Ipek Erseven, Emilia Ewen Benns, Molly Tate, Ethan L Morgan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13364667.txt.
Description
Fin Brown and co-authors test a drug pairing against head and neck cancer cells in a 2026 study. These cancers often resist chemo and radiation, and a survival pathway helps the cells hold out. The drug b-AP15 blocks part of that pathway and can kill such cells on its own. The team asked whether it also makes cells weak to TRAIL, a signal that tells cancer cells to die.
Lab tests said yes. The drug raised levels of a TRAIL receptor called DR5 on the cells. That rise needed stress signals inside the cell, namely reactive oxygen species and the JNK pathway. Blocking a survival gene also played a role. Pairing the drug with a second class of blockers killed even more cells. The authors call for animal studies next.
Catalog record
| CREATOR | Fin T A Brown, Lucy Quesne, Louisa M Wootton, Holly Foxell, Ipek Erseven, Emilia Ewen Benns, Molly Tate, Ethan L Morgan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |